1040377-02-3

Basic information

• Product Name: 4-Bromo-1-tetrahydro-2H-pyran-4-yl-1H-pyrazole
• Synonyms: 4-Bromo-1-tetrahydro-2H-pyran-4-yl-1H-pyrazole;4-bromo-1-(oxan-4-yl)pyrazole
• CAS NO: 1040377-02-3
• Molecular Formula: C₈H₁₁BrN₂O
• Molecular Weight: 231.08974
• Product Categories: Halides;Pyrazoles & Triazoles
• Mol File: 1040377-02-3.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 328.5±32.0 °C(Predicted)
• Appearance: /
• Density: 1.66±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 0.73±0.19(Predicted)
• CAS DataBase Reference: 4-Bromo-1-tetrahydro-2H-pyran-4-yl-1H-pyrazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-1-tetrahydro-2H-pyran-4-yl-1H-pyrazole(1040377-02-3)
• EPA Substance Registry System: 4-Bromo-1-tetrahydro-2H-pyran-4-yl-1H-pyrazole(1040377-02-3)

Safety Data

• Hazardous Substances Data: 1040377-02-3(Hazardous Substances Data)

Usage

General Description

4-Bromo-1-tetrahydro-2H-pyran-4-yl-1H-pyrazole is a chemical compound that belongs to the class of pyrazole derivatives. It is a heterocyclic compound containing both a pyran and a pyrazole ring, with a bromine atom attached to the pyran ring. 4-Bromo-1-tetrahydro-2H-pyran-4-yl-1H-pyrazole has potential applications in the field of medicinal chemistry, particularly as a building block for the synthesis of biologically active compounds. It may also have use in the development of new pharmaceuticals or agrochemicals. The specific properties and potential uses of this compound would depend on further research and experimentation.

Upstream product

• 25637-18-7 4-iodotetrahydropyran 
• 2075-45-8 4-bromo-1H-pyrazole 
• 1768-64-5 4-chlorotetrahydro-2H-pyran 
• 25637-16-5 4-bromotetrahydro-2H-pyran 
• 97986-34-0 toluene-4-sulfonic acid tetrahydropyran-4-yl ester 
• 2081-44-9 Tetrahydro-pyran-4-ol 
• 134419-59-3 4-oxanyl methanesulfonate 

Downstream Products

• 1003846-21-6 1-(tetrahydro-2H-pyran-2-yl)-4-(4_,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 
• 1394930-20-1 2-amino-N-[1-(2,6-dichloro-3-fluorophenyl)ethyl]-5-[1-(oxan-4-yl)-1H-pyrazol-4-yl]pyridine-3-carboxamide 
• 1040377-03-4 1-(tetrahydro-2H-pyran-4-yl)-4-(4,4,5,5 -tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole 

Relevant articles and documents

Lead Optimization of 3,5-Disubstituted-7-Azaindoles for the Treatment of Human African Trypanosomiasis

Neglected tropical diseases such as human African trypanosomiasis (HAT) are prevalent primarily in tropical climates and among populations living in poverty. Historically, the lack of economic incentive to develop new treatments for these diseases has meant that existing therapeutics have serious shortcomings in terms of safety, efficacy, and administration, and better therapeutics are needed. We now report a series of 3,5-disubstituted-7-azaindoles identified as growth inhibitors of Trypanosoma brucei, the parasite that causes HAT, through a high-throughput screen. We describe the hit-to-lead optimization of this series and the development and preclinical investigation of 29d, a potent antitrypanosomal compound with promising pharmacokinetic (PK) parameters. This compound was ultimately not progressed beyond in vivo PK studies due to its inability to penetrate the blood-brain barrier (BBB), critical for stage 2 HAT treatments.

SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE

In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): or and pharmaceutically acceptable salts thereof, wherein, R1, R2, and R3 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

AMINOPYRIDINE DERIVATIVES AS TAM FAMILY KINASE INHIBITORS

Provided herein are aminopyridine derivatives and pharmaceutical compositions that are useful as TAM family kinase inhibitors.